Additionally, CD19+/CD5+ cells in both spleen (Fig. 7E, left) and bone marrow (Fig. 7F, left) of DT-061-treated mice exhibited a reduced viability compared with vehicle, as measured by Annexin-V single staining, suggesting that reduction in leukemic burden induced by DT-061 in these organs is due to decreased tumor cell survival. This evidence concerns the gene CD19 and neoplasm.